Givaudan sales and earnings
This article was originally published in The Rose Sheet
Executive Summary
Swiss fragrance firm booked $2.34 bil. in sales for FY 2006, it announces Feb. 20. Both fragrance and flavor divisions of the company achieved above market sales growth despite continued ingredients streamlining, which impacted annual sales by $26.6 mil. The fragrance division recorded sales of $984.8 mil., a rise of 8.2% from FY 2005, driven by double-digit growth in fine fragrances and strong performances from consumer products and specialty ingredients. Givaudan attributes expansion of its market position in FY 2006 to new sales and growth strategies; the firm acquired Quest International in November for $2.3 bil. (1"The Rose Sheet" Nov. 27, 2006, In Brief)...
You may also be interested in...
Givaudan grows
Swiss luxury firm will acquire Quest International, UK-based Imperial Chemical Industries' fragrance and flavor business, for $2.3 bil., it announces Nov. 22. The acquisition will expand Givaudan in all segments of the fragrance and flavor industry, a plan which is "fully in line with Givaudan's strategy to focus on developing markets and to capture opportunities in key segments and at key clients," company says. The decision will help grow the brand in Asia Pacific, Latin America, Eastern Europe, Africa and the Middle East, according to Givaudan. Subject to regulatory approval, the deal is expected to close in Q1 2007...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.